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Abstract
Appetite regulation by nutritional intervention is required early in life that involves the anti-aging
gene Sirtuin 1 (Sirt 1) with Sirt 1 maintenance of other cellular anti-aging genes involved in cell
circadian rhythm, senescence and apoptosis. Interests in anti-aging therapy with appetite regulation improve an individual’s survival to metabolic disease induced by gene-environment interactions by maintenance of the anti-aging genes connected to the metabolism of bacterial lipopolysaccharides, drugs and xenobiotics. Interventions to the aging process involve early calorie restriction with appetite regulation connected to appropriate genetic mechanisms that involve mitochondrial biogenesis and DNA repair in neurons. In the aging process as the anti-aging genes are
suppressed as a result of transcriptional dysregulation chronic disease accelerations and connected to insulin resistance, non-alcoholic fatty liver disease (NAFLD) and neurodegenerative
diseases such as Parkinson’s disease and Alzheimer’s disease. Interests in the gene-environment
interaction indicate that the anti-aging gene Sirt 1that regulates food intake has been repressed
early in the aging process in various global populations. The connections between Sirt 1 and other
anti-aging genes such as Klotho, p66Shc (longevity protein) and Forkhead box proteins (FOXO1/
FOXO3a) have been associated with programmed cell death and alterations in these anti-aging
genesregulate glucose, lipid and amyloid beta metabolism that are important to various chronic
diseases.
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1. Introduction

The hypothalamus is involved with many biological functions and includes appetite and body weight control,
feeding, emotion, memory, thermoregulation, fluid balance and insulin regulation [1]-[3]. The hypothalamic nuclei that are involved in food intake include the arcuate nucleus, the paraventricular nucleus, the lateral hypothalamic area, the ventromedial nucleus and dorsomedial nucleus. Arcuate nucleus neurons at the bottom of the
hypothalamus near the third ventricle have direct contact with peripheral satiety factors like leptin and insulin.
Neurons in the hypothalamus are responsible for various connections to other brain regions and one of the important functions of the hypothalamus is control of the daily light dark cycle. The suprachiasmatic nucleus
(SCN) that coordinate the neuronal, humoural systems and the circadian rhythms activate the arcuate nucleus
that releases neuropeptide Y (NPY) and agouti related protein (AgRP) that control physiological functions
(body) temperature, melatonin release, glucocorticoid secretion and behavioural functions (feeding and memory). The SCN and peripheral oscillators are altered by food availability with calorie restriction important in the
maintenance of the SCN and the synchrony of the peripheral clocks. The neurons in the hypothalamus (appetite
centre) are sensitive to apoptosis and become senescent early in life with relevance to global chronic diseases
such as non-alcoholic fatty liver disease (NAFLD), obesity and diabetes.
In neurodegenerative diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) neurons in
specific regions of the brain become apoptotic later in life but may not involve the neurons in the appetite centre.
Neurodegenerative diseases such as PD and AD have become the cornerstone of brain research with appetite
dysregulation and insulin resistance now closely connected to these diseases. Early neuron transcriptional dysregulation that involves the SCN leads to food intake disorders and it cannot be excluded that neurons in the appetite centre are defective early in life in global populations with appetite dysregulation associated with neurodegenerative diseases such as PD and AD. Appetite dysregulation is connected to the anti-aging gene Sirtuin 1
(Sirt 1) that is connected to the circadian rhythm with effects on the endocrine and metabolic systems that involve diseases of the adipose tissue, heart, liver, pancreas and brain [4]-[6]. Neuron apoptosis and survival
[7]-[10] is determined by Sirt 1 and other anti-aging genes and interventions that prevent down regulation of
anti-aging genes may allow appetite regulation with prevention of other chronic diseases. The rise in NAFLD in
global populations [11] [12] has required early intervention with connections to the severity of diseases such as
obesity, diabetes and neurodegenerative diseases. Interests in the calorie restriction with stabilization of antiaging genes have accelerated in recent years to delay and prevent programmed cell death linked to the various
chronic diseases (Figure 1). Interventions such as diet and lifestyle in chronic diseases such as obesity, diabetes
and cardiovascular disease involve abnormal post-prandial lipid metabolism [13] [14]. Diet is strongly associated with insulin and insulin like growth factor-1 (IGF-1) with cell senescence (mitochondrial apoptosis) and
genotoxic stress linked to the global NAFLD and neurodegeneration [15]-[21].
Interest in genomics that leads to the identification of novel genetic pathways assists in the treatment of various chronic diseases with the new knowledge that may delay early programmed cell death pathways in cells.
Nutritional interventions that are controlled by the consumption of a low calorie diet indicate the maintenance of
connections between Sirt 1 and other anti-aging genes such as Klotho, p66Shc (longevity protein) and FOXO1/
FOXO3a that have been connected to the cell death by effects on glucose, lipid and amyloid beta metabolism.
These anti-aging genes in neurons are involved in transcriptional regulation with effects that are important to
SCN control of food intake and to the survival and stability of neurons. High fat diets that induce cell senescence are linked to cell transformation and are associated with liver cell dysfunction (NAFLD), adipogenesis
disorders (obesity) and other organ diseases (Figure 1). The severity of endocrine and metabolism disorders are
associated with poor neuron survival with early neuron transformation that leads to appetite dysregulation with
overeating linked to metabolic disease. Major advances in the early diagnosis of diseases such as NAFLD and
neurodegenerative disease associated with obesity and diabetes are required. Diagnostic blood assays such as
plasma cholesterol measurements may not determine early senescence and programmed cell death [22] and extensive blood testing that is now underway in global populations may not be relevant to liver cell or neuron
apoptosis (neurodegenerative diseases). The role of diets that control the absorption of bacterial lipopolysaccharides (LPS) are critical to prevent NAFLD and neurdegeneration [23] and the repression of anti-aging genes are
possibly linked to LPS with the acceleration of appetite dysregulation and chronic diseases. The effects of LPS
may also interfere with IGF-1 mediated expression of anti-aging genes with IGF-1/p53 transcriptional regulation
linked to Sirt 1 regulation of cell survival in aged and stressed cells [15]-[21]. To improve appetite dysregulation
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Figure 1. Anti-aging strategies involve the maintenance of appetite regulation and
insulin resistance that are connected to the anti-aging genes that are suppressed early
in life. Appetite dysregulation accelerates abnormal post-prandial lipid metabolism
and NAFLD in global populations and early intervention is required to prevent the
severity of diseases such as obesity, diabetes and neurodegenerative diseases. Appetite
maintenance improves the endocrine and metabolic system that is connected to blood
brain barrier (BBB) disease and various organs diseases.

and prevent overeating that is linked to gene-environment effects (stress) on metabolic disease the maintenance
of the apelinergic pathway [24] early in life is essential. Nitric oxide (NO) is involved in appetite regulation and
NO disturbances have been reported in various chronic diseases [25]. Diets that are high in NO override cell NO
maintenance that is controlled by Sirt 1 relevant to endocrine, metabolic disease and thrombosis [24]-[27]. The
effects of stress and xenobiotics (environment) are associated with cell NO disturbances that prevent the reversal
of cell senescence (Figure 2). The nutritional diets that maintain the anti-aging genes and NO cell homeostasis
possibly involve Sirt1/IGF-1 [29]-[36] with the effects of dietary LPS involved in the NO dyshomeostasis, neuron senescence and apoptosis.
Zinc deficiency and chronic disease has become important with zinc levels relevant to hormone bioactivity [3],
Sirt 1 activity [28] and IGF-1 functions [37] [38]. Zinc supplementationhas become important to LPS toxicity
with relevance to inflammation in various global populations [39] [40]. Appetite regulation has been associated
with various neuropeptides such as brain derived neurotrophic factor (BDNF) and NPY, hormones such as insulin, adiponectin, leptin and various intestinal peptides [3] [41]-[43]. The role of zinc and Sirt 1 that involved in
the regulation of the anti-aging genes has become important since repression of these genes do not maintain the
action of the various neuropeptides, hormones and intestinal factors involved in appetite regulation with relevance to chronic diseases. Anti-aging therapy that maintains appetite regulation improves an individual’s survival against autonomous disease induced by the environment (bacterial lipopolysaccharides, drugs, xenobiotics)
in various communities. Diets that are nutritional activate cellular anti-aging genes with the prevention of cell
senescence and apoptosis. Appetite regulation maintains the autonomic innervation of the liver by the brain with
the maintenance of rapid post-prandial lipid metabolism [13] [14] and the prevention of diseases of the adipose
tissue, heart, and pancreas.

2. Repression of Anti-Aging Genes Determine Food Intake Regulation, Insulin
Resistance and Neurodegenerative Disease
Overnutrition in chronic disease is involved with central nervous system dysregulation of neuropeptides with
abnormal peripheral hormone signalling from the pancreas (insulin), adipose tissue (leptin and adiponectin) and
gastrointestinal tract (neuropeptides) involved in chronic diseases. The increases in global chronic disease in the
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Figure 2. The acceleration of chronic diseases involve NO disturbances
linked to stress, consumption of unhealthy diets and xenobiotics (gene-environment interactions). Endocrine and metabolic diseases are linked to appetite
dysregulation with NO disturbances that involve defective apelinergic pathways. Nutritional diets maintain the anti-aging genesand NO cell homeostasis
with the importance of Sirt1/IGF-1 interactions in NO homeostasis, neuron
senescence and apoptosis. Sirt 1 is involved with the circadian rhythm and
platelet apoptosis with relevance to thrombosis and embolism.

past 20 years have indicated that insulin resistance and organ suicide are closely connected. The role of the mitochondria in organ function is critical with increased mitochondrial apoptosis with accelerated aging. The role
of anti-aging genes in organ disease has become of central interest to maintain mitochondria functions and the
identification of longevity genes that determine their function is critical to the maintenance of chronic diseases.
The association between senescence and chronic disease now indicate that the anti-aging genes have been suppressed (autonomous disease) and insulin resistance, IGF-1 levels and neuropeptide disturbances are closely
connected to mitochondria aging and cell senescence. Defective anti-aging genes are associated with glucose
dysregulation with inhibition of insulin signalling involved with mitochondrial apoptosis. In SCN neurons
within the brain the anti-aging genes that are involved with appetite regulation become altered by altered gene
expression and abnormal posttranscriptional regulation closely connected to appetite dysregulation. The SCN
synchrony between neurons is essential to maintain circadian rhythms and disturbances between neurons are associated with autonomous neuron disease linked to the anti-aging gene repression and liver dysfunction.
The gene that is involved in the regulation of food intake is Sirtuin 1 (Sirt 1) that is linked to life span, obesity
and cardiovascular disease with effects on NAFLD, inflammation, energy metabolism, cognition, mitochondrial
biogenesis, neurogenesis, glucose/cholesterol metabolism and amyloidosis. Sirt 1 is a nicotinamide adenine dinucleotide (NAD+) dependent class III histone deacetylase (HDAC) that targets transcription factors to adapt
gene expression to metabolic activity and is involved in the deacetylation of the nuclear receptors with its critical involvement in insulin resistance. Sirt 1 is also involved in telomerase reverse transcriptase and genomic
DNA repair with its involvement in telomere maintenance that maintains chromosome stability and cell proliferation. Sirt1 is essential for neurogenesis and calorie restriction activates Sirt1 with effects on longevity by
modulation of phosphoinositide 3 kinase pathways and age associated cardiovascular changes. Tissue nuclear
receptors undergo deacetylation of histone and non-histone targets by Sirt 1 that targets transcription factors
peroxisome proliferator-activated receptor-gamma coactivator (PGC-1 alpha), p53, pregnane x receptor (PXR)
to adapt gene expression to metabolic activity, insulin resistance and inflammation. Sirt 1 is linked to glucose
regulation with the involvement of Forkhead box protein O1 (FOXO1) deacetylation (apoptosis) that involve
p53 transcriptional dysregulation and peroxisome proliferator activated receptor (PPAR) gamma nuclear receptor. Furthermore Sirt 1/p53 interactions may regulate adipocytokines and immune responses that may be important to NAFLD, obesity and neurodegeneration. Interests in calorie restriction, appetite regulation and neurodegeneration that involve Sirt 1 mediated regulation of other anti-aging genes involve p53 and FOXO deacetyla-
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tion that has attracted interest in relation to autonomous disease of the brain and liver. In these tissues Sirt 1 is an
important gene involved in maintenance of the mitochondria and deacetylation of the transcriptional factor
FOXO3a that represses Rho-associated protein kinase-1 gene expression with activation of the non amyloidogenic α-secretase processing of the amyloid precursor protein and reduction of amyloid beta (Aβ) generation in
neurons. Sirt 1 is also involved with hepatic cholesterol regulation with effects on liver nuclear receptors involved with cholesterol flux and metabolism. Overnutrition is associated with the repression of Sirt 1 and other
anti-aging genes (Figure 3) such as Klotho, p66Shc (longevity protein) and FOXO1/FOXO3a that is now connected to autonomous diseases of the brain and liver with SCN disturbances induced by Sirt 1 repression and
IGF-1 dysregulation involved in programmed cell death relevant to various chronic diseases such as obesity,
diabetes, PD and AD.

2.1. Klotho
The klotho (KL) gene is composed of 5 exons and encodes a type-I single pass transmembrane protein (1014amino acid-long), short intracellular domain (10-amino acidlong). The extracellular domain is composed of two
domains, termed KL1 and KL2, with weak homology. Klotho knockout mice have a short life span with increased oxidative stress associated with atherosclerosis, osteoporosis, infertility, and cognitive decline. The gene
for the mammalian KL has two transcripts encode a long type I transmembrane protein and a short secreted protein that is released from the cell membrane and found in the serum and cerebrospinal fluid (CSF) [44] [45]. Sirt
1 and its close involvement as a histone deacetylase may be involved with Kotho gene expression and Sirt 1
downregulation may be intimately involved in the secretion and release of the protein into the serum or CSF.
Resveratrol is closely involved in Sirt 1 upregulation and studies indicate that Klotho gene expression and secretion is upregulated by resveratrol [46]. Klotho gene has been identified as an important regulator of age related
diseases and is involved with cell senescence by upregulation of p21 [47]. Klotho is an anti-aging gene and in
Klotho-deficient mice Klotho has been associated with a premature aging-like syndrome. These results demonstrate that Klotho normally regulates cellular senescence by repressing the p53/p21 pathway that is activated by
DNA damage and causes G(1)-phase arrest in mammalian cells. Klotho has been reported as a secreted Wnt antagonist and a tumor suppressor [48]. Epigenetic silencing of klotho has been shown as a major pathway with
the involvement of histone deacetylation in the transcriptional repression of Klotho is correlated with promoter

Figure 3. The anti-aging gene Sirt 1 is associated with transcriptional regulation and linked to insulin
resistance, cancer and NAFLD. Sirt 1 regulation of p53, PGC1-alpha, PXR, PPAR, AMPK, FOXO1
involve nutrient, xenobiotic metabolism with relevance to DNA repair and the immune system. Transcriptional regulation of Sirt 1/p53 interactions are associated with alpha synuclein and amyloid beta
interactions with the abnormal p53 transcriptional regulation of the anti-aging genes (Sirt 1, Klotho,
p66Shc (longevity protein), FOXO1/FOXO3a) associated with IGF-1 and cancer.
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CpG hypermethylation and linked to Sirt 1 gene silencing that involve CpG island methylation. Klotho protein
has been indicated to be a hormone that inhibits the intracellular insulin/IGF-1 signaling cascade [49] [50]. In
other studies Klotho has been shown not inhibit IGF-1 and/or insulin signaling in various cells such as HEK293,
L6, and HepG2 cells and indicate against the role of Klotho in insulin resistance as an important regulator of
aging. Klotho gene expression was not associated with telomere length and the association with aging via other
mechanisms [51]. Klotho has been associated with cognition [52] and chronic kidney disease via the fibroblast
growth factor 23 but klotho levels have remained unchanged [53].

2.2. p66Shc
The gene SHC1 is located on chromosome 1 and encodes 3 main protein isoforms: p66Shc, p52Shc and p46Shc
and differ in molecular weight. p66Shc, a 66 kDa proto-oncogene Src collagen homologue (Shc) adaptor protein
is a longevity protein and has many effects involved with cell receptor tyrosine kinase signal transduction, nutrient metabolism and increased levels of p66Shc (Ser phosphorylation) have been shown to block mitosis, inhibit glucose metabolism and associated with the regulation of reactive oxygen species induced cell apoptosis
[54]-[57]. p66Shc antagonizes insulin and mTOR effects which limits glucose uptake and inhibits anabolic metabolism [58] [59]. The p66shc protein plays key role in oxidative stress, stroke, metabolic disease in various
organs and tissues in obesity and diabetes [60]-[64]. The p66Shc isoform has inhibitory effects on the Erk pathway [65] in skeletal muscle myoblasts, actin cytoskeleton polymerization and glucose transport. p66Shc inhibits
ERK1/2 activity and antagonize mitogenic and survival abilities of T-lymphoma Jurkat cell lines. The
MAPK/Erk signaling cascade is activated by a wide variety of receptors involved in growth and differentiation
including receptor tyrosine kinases (RTKs), integrins, and ion channels. Oxidized lipids and LDL have been
shown to stimulate p66Shc expression that is associated with abnormal redox balance, endothelial dysfunction
and cardiovascular disease [66]-[68]. p66Shc is involved with the expression of p53 and p53 isoform (p44/p53),
oxidative stress and G2M cell cycle arrest [69]-[71]. The induction of angiotensin II regulated p66Shc is controlled by stress activated p53 and indicates that post transcriptional regulation by p53 of p66Shc is essential for
endothelium dependent vascular relaxation [72]. Sirt 1 is primarily involved in the deacetylation of p53 with
control of p66Shc cellular senescence associated with the progression of NAFLD. Repression of p66Shc expression by Sirt 1 has been shown to be involved with liver injury and hyperglycemia induced endothelium dysfunction [73]. Palmitic acid is an inhibitor of Sirt 1 and palmitate has been shown to increase p66Shc (Ser phosphorylation) in pancreatic beta cells [74]. p53 is closely involved with the palmitate-induced increase in p66Shc
expression and beta cell apoptosis. Sirt 1 that is actively involved in Aβ metabolism in neurons and Aβ has now
been connected to the phosphorylation of p66Shc at the serine 36 residue with increased oxidative stress that
leads to cell death [75] [76]. Antioxidants have been shown to be involved with reduced oxidative stress by interfering with the phosphorylation of p66Shc. Sirt 1 has effects on brain and liver alpha-synuclein and Aβ metabolism closely linked metabolic disease [77] [78] with effects of p53 transcriptional regulation by intracellular
alpha-synuclein and Aβ metabolism in the liver and brain linked to the regulation of anti-aging genes and cellular apoptosis [78] [79].

2.3. FOXO3a
FOXOs belong to the O subclass of the Forkhead family of transcription factors which are characterized by a
Forkhead DNA binding domain. There are three main proteins (FOXO1, FOXO3a and FOXO4) from which
FOXO3a protein is considered to be a regulator of cancer and aging [80]-[83]. FOXO1 proteins are involved
with adipocyte lipid metabolism and ROS-dependent cascades. FOXO3a is found in the nucleus but is redistributed to the cytosol by the actions of ROS and activation of this pathway (insulin/insulin-like growth factor-1
(IGF-1)/phosphatidylinositol-3 kinase (PI3K)/Akt/FOXO3a) is associated with senescence [84]. p66Shc participates in Akt signaling pathway and is involved with inactivated FOXO3a and ROS effects that involve activated
p38 and JNK and inactivated by Akt kinase in cells. Sirt 1 has been shown to deacetylate FOXO3 and FOXO4
with the regulation of FOXO-induced apoptosis and cell-cycle arrest not connected to p53 deacetylation. Sirt 1
has been shown to interact with FOXO3a and induce cell apoptosis [85] [86]. Nuclear Sirt 1 actively involved in
Aβ metabolism and possibly regulates FOXO associated senescent effects with control of cell survival. Klotho
has been shown to activate FOXO and to inhibit the insulin/IGF-1/PI3K/Akt signaling cascade. The connections
between Sirt 1 and Kotho for cell senescence possibly are connected via FOXO1/FOXO3a mediated glucose
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homeostasis and ROS pathways. Bacterial lipopolysaccharides (LPS) are involved in the repression of Sirt 1
with the actions on other anti-aging genes. Zinc is the activator of Sirt 1 function with LPS closely connected to
zinc deficiency with zinc supplementation essential to reduce LPS toxicity [38] [39]. Sirt 1’s effects on cellular
cholesterol homeostasis is by its deacetylase activity and ubiquitination of liver X receptor (LXR) proteins with
the regulation of ATP-binding cassette transporter (ABCA1) and sterol regulatory element-binding protein
1cinvolved in cell cholesterol homeostasis [78] [79]. LPS interferes with Sirt 1 and ABCA1 interactions by inhibition of cholesterol flux via LXR-ABCA1 pathways [78] [79]. Sirt 1 regulation of PGC1 alpha is well understood with PGC1 alpha involved in the inactivation of prostaglandain E2 (PGE2) with fat accumulation [11].
LPS is involved in the biosynthesis of PGE2 with LPS effects in the liver and other cells that override Sirt 1and
PGC1 alpha effects in these cells [87] [88]. The major effects of Sirt 1 as a deacetylase is regulation of the transcription factor p53 involved in the regulation of cell glucose and cholesterol metabolism [79]. LPS is involved
in the post-transcriptional regulation of p53 with interference of Sirt 1/p53 cell regulation pathways involved in
cell maintenance [79]. LPS induces mitochondrial apoptosis with toxic effects on the SCN neurons involved
with appetite regulation that involve Sirt 1 dysregulation linked to anti-aging genes [78] [79]. IGF-1 levels and
its connections to Sirt 1 and the anti-aging genes possibly involve corruption by LPS with LPS effects that involve dysregulation ofcircadian regulation of IGF-1 with IGF-1 effects on nuclear genes (cancer) and mitochondria within cells [17]-[19] [89]-[91]. Sirt 1 and its regulation of the SCN and appetite centre are inhibited by
LPS via interference of the Sirt 1/p53 pathways that involve the other anti-aging genes.

3. Dysregulation of Neuropeptides and Endocrine Hormones by LPS Determine
Appetite and Metabolism Disorders
The SCN in the brain is closely involved with appetite regulation and LPS induced posttranscriptional regulation
in neurons is now closely connected to appetite dysregulation. The SCN synchrony between neurons is essential
to maintain circadian rhythms and disturbances between neurons are associated with autonomous neuron disease
linked to appetite dysregulation. LPS has a number of effects on various cells and tissues in the periphery and in
the brain. LPS induces dyslipidemia and NAFLD with effects on apolipoproteins (apo E, apo AI), acute phase
proteins, cytokines, albumin, alpha synuclein and amyloid beta [77] [78]. Its preference for binding to cholesterol and sphingomyelin sites on cell membranes indicates its role in the electrostatic interaction of amyloid beta
[23] [77]. LPS has marked effects on receptors and on the astrocyte-neuron interaction with the induction of
neuroinflammation [77]. LPS effects on the sleep/wake cycle determines food intake regulation and LPS effects
on appetite regulation involves Sirt 1 repression and alpha synuclein/IGF-1 metabolism [78] [92]-[95]. Neurons
in the hypothalamus are responsible to various brain regions and LPS induction of nuclear, mitochondria and
cell membrane interactions induces autonomous cell behaviour with appetite dysregulation linked to reorganization cell signalling and astrocyte-neuron synchrony in the brain. Autonomous disease interferes with the effects
of neuropeptides and hormones that are no longer effective and are now connected to nuclear receptors dysfunction associated with the anti-aging genes. Appetite regulation has been associated with various neuropeptides
such as BDNF and NPY, hormones such as insulin, adiponectin, leptin and various intestinal peptides [96].
The interests in LPS in the induction of autonomous neuron disease involve inflammation with the connections to poor neuropeptide/receptor and peripheral hormones interactions that promote appetite dysregulation in
the brain. NO has been clearly linked to food intake regulation and autonomous neuron disease induced by LPS
is relevant overeating and metabolic disease in global populations (Figure 2). The effects of LPS induce mitochondrial apoptosis with NO dyshomeostasis [97]-[100] and corrupt appetite regulation by interference with
neuropeptides and peripheral hormones that are also involved in the maintenance of mitochondrial stability. The
effects of LPS on nuclear Sirt 1 repression in neurons disturb Sirt 1 regulation of cell NO metabolism with Sirt 1
linked to mitochondrial biogenesis [79]. The effects of LPS in the brain and the liver corrupt the autonomic innervation of the liver by the brain [101] with the liver clocks under autonomous regulation with sensitivity to
disturbed post-prandial metabolism, liver steatosis and NAFLD. Interest in metabolic disorders indicate that the
communication between the gastrointestinal tract neuropeptides involve the hypothalamus and brain stem [3].
These regions of the brain integrate peripheral signals such as various factors released from the gut and adipose tissue that have effects on neuronal activity of the hypothalamus and brain stem that control appetite regulation. In response to food intake various gut and adipose tissue hormones have effects on the hypothalamus that
release various neuropeptides that effect appetite, food intake and energy balance. Cholecystokinin (CCK) is an
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intestinal hormone and after a meal CCK levels rise to inhibit food intake. Other peptides involved in appetite
regulation include glucagon like peptide (GLP-1) that increases in the blood plasma released from the L cells of
the gastrointestinal tract. Pancreatic islet beta cells release insulin and another peptide referred to as amylin is
released with relevance to reduced food intake. Other proglucagon cleavage peptides including oxyntomodulin
(OXM) and peptide YY (PYY) are secreted with GLP-1 in response to high calorie foods. Pancreatic polypeptide (PP) is secreted from the pancreatic islets and is similar in structure to PYY with reduction in food intake
after administration to rodents and humans. PP has effects on gastric ghrelin and gene expression of hypothalamic peptides such as NPY and AGRP that control food intake. Ghrelin is 28 amino acid peptide hormone and
has been characterized as an appetite stimulating hormone with effects on appetite control related to hypothalamic NPY/AgRP neurones which express the ghrelin receptors [3].
Future therapies that involve control of body size and adiposity will involve assessment of diets that reduce
LPS absorption [23] with relevance to LPS effects on the hypothalamus and on the poor regulation of various
intestinal and brain neuropeptides that influence appetite regulation. Influence on appetite regulation and feeding
are also related to leptin, melanortin, adiponectin, melanin concentrating hormone (MCH), orexins and endocannabinoids that communicate with peripheral signals such as nutrients (glucose, amino acids, fatty acids) and
gastrointestinal peptide hormones such as CCK and ghrelin. Thyroid hormones may act directly on the hypothalamic appetite circuits and signalling factors such as thyroid stimulating hormone, triiodothyronine (T3) and
thyroxine (T4) have recently shown to directly influence food intake. Hypothalamic control of appetite regulation and energy expenditure not only involves the hypothalamus but also the hypothalamic pituitary axis (HPT).
Recent evidence indicates that the HPT axis can control food intake and effects on appetite and body weight is
mediated by thyroid hormones and LPS has become important to appetite regulation [102] [103]. Interests in the
neuroendocrine system, energy metabolism and peripheral cholesterol metabolism have increased with the
strong genetic identification andinvolvement NPY in plasma cholesterol regulation.
The CNS and its control of lipidmetabolism has identified hypothalamic NPY with evidence that NPY has
effects onY1 receptors to promote hepatic lipoprotein secretion to promote VLDL secretionvia the sympathetic
nervous system [104] [105] and on Y2 receptors to promote feeding. Sirt 1 regulation of BDNF [106]-[108] has
been shown (Figure 4) and associated with altered NPY levels in the brain [109] [110] and several studies have
indicated its involvement in neuronal plasticity, behaviour, appetite control andbody weight regulation. BDNF is
involved in the regulation of food intake and the levels of BDNF controlled by high fat diets. In mature neurons
the BDNF peptide is involved with the regulation of synaptic plasticity and neuro transmission in the peripheral

Figure 4. Bacterial LPS suppresses Sirt 1 expression with effects on
neuropeptides such as brain derived neurotrophic factor, neuropeptide Y
and IGF-1 that are involved in the appetite regulation (food intake) in
the brain and in the periphery LPS interrupts hepatic glucose, lipoprotein and cholesterol metabolism. LPS is involved in cell zinc homeostasis with the importance of zinc relevant to the maintenance of Sirt 1 activity and the function of hormones such as insulin and the adipokines (adiponectin, leptin) involved in appetite regulation in the hypothalamus.
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and central nervous system. BDNF is involved in regulation of CB1 receptor expression and the proliferation,
survival and maintenance of neurons. In individuals with the metabolic syndrome Sirt 1 downregulation is possibly related to BDNF levels [111], IGF-1 levels and abnormal NPY regulation involved with appetite dysregulation and neurodegeneration.
Zinc deficiency has marked effects on brain zinc homeostasis and is associated with alterations in behaviour,
learning and mental function. Under stress, anxiety and depression disorders zinc levels alter with marked effects on health and well being of the individuals. Stress has been linked to body weight regulation and evidence
suggests zinc’s involvement in the molecular mechanisms of brain function and appetite control. Zinc is involved with regulation of leptin, insulin and adiponectin levels, adipose tissue cytokines (interleukin 2 and tumour necrosis factor) with long term effects on appetite regulation in the brain.
In zinc deficiency NPY levels in the hypothalamus are increased and release of NPY from the paraventricular
nucleus is impaired with effects on regulation of food intake [112] [113]. In zinc deficiency NPY is unable to
bind to its receptors to intiate an orexigenic response. Zinc is involved in the expression of brain BDNF and
NPY synthesis and its effects on insulin, leptin and adiponectin [3] in the peripheryindicates its role in the close
relationship between appetite control and cholesterolhomeostasis. Zinc is an activator of Sirt 1 and plays a critical role in the biology of p53 that is involved in the binding of p53 to DNA [114]. Interests in alpha-synuclein
and food intake have increased [92] [93] and its relevance to p53 transcriptional regulation has been shown with
LPS involvement [78] [79]. LPS regulation of apo E (23) has become important with relevance to apo E suppression of food intake [115]-[117] and LPS effects on leptin synthesis may determine appetite regulation [118]
[119]. Leptin is a 16 kda protein identified in 1994 (14) is synthesized by fat cells and acts as a satiety factor at
the hypothalamus mediated through the leptin receptor. The amount of leptin released is proportional to the size
of adipose tissue and regulates food intake. LPS has effects on adipose tissue with release of free fatty acids associated with insulin resistance [120]. Dietary fat that promotes LPS absorption may determine apo E and leptin
synthesis in the hypothalamus with relevance to chronic automomic disease that involveszinc deficiency, appetite dysregulation and insulin resistance.

4. Anti-Aging Therapy Involves Reversal of Appetite Disorders in Autonomous
Chronic Diseases
In the aging process appetite dysregulation (overeating) is connected to the suppression of the anti-aging genes
as a result of transcriptional dysregulation. Interests in the gene-environment interaction [121] [122] indicate
that the anti-aging gene Sirt 1 that regulates food intake is repressed early in the aging process in various global
populations. Repression of Sirt 1 and other anti-aging genes such as Klotho, p66Shc (longevity protein) and
FOXO1/FOXO3a lead to abnormal regulation of glucose, lipid and amyloid beta metabolism that are associated
with programmed cell death in the liver and brain. Dietary effects on stress sensitive anti-aging genes (repression) may be associated with Sirt 1 downregulation with appetite dysregulation and accelerated disease progression. Anti-aging therapy that maintains appetite regulation improves an individual’s survival against autonomous disease induced by the environment in various communities. Bacterial lipopolysaccharides, drugs, and
xenobiotics consumed early in life induce autonomous chronic disease and corrupt the Sirt 1 circadian clock
gene with dysregulation of other cellular anti-aging genes now associated with cell senescence and apoptosis.
Furthermore the lack of ingestion of nutritional doses of phosphatidylinositol (appetite regulation) leads to liver
steatosis and acceleration to NAFLD. In the current global NAFLD in developing countries [122] [123] the induction of autonomous liver disease by consumption of high calorie diets that contain LPS, xenobiotics and
drugs is now relevant to neurodegenerative diseases such as PD and AD. LPS and xenobiotics inactivate liver
cells (autonomous liver disease) with relevance to the defective peripheral sink abeta clearance pathway that is
now relevant to many chronic diseases [11] [124] that before may have been previously only associated with
neurodegeneration [77]. The role of anti-aging genes in various communities in the developing world may be
altered early in life with the acceleration of various diseases [11]. In the developed world the xenobiotic free diet
and appropriate zinc consumption may activate hepatic nuclear receptors and with the metabolic syndrome the
malfunction of various organ diseases may not be associated with the insulin resistance epidemic [125]. To
maintain the cell anti-aging gene mechanisms and prevent early programmed cell death diets that are very low
carbohydrate diets need to be ingested to avoid the intestinal absorption of LPS into the blood that is found in
various foods [14]. The low calorie diet will maintain the nuclear Sirt 1 activity with relevance to p66Shc
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mechanisms that are sensitive to the ingestion of high palmitic acid and leads to cell cycle dysregulation with
cell apoptosis [74] [126]. Short chain fatty acids (SCFA) have become important to appetite regulation with the
consumption ofacetate, propionic acid and butyric acid at therapeutic doses applicable to central appetite regulation [127] [128]. Butyric acid has been associated with the inhibition of zinc associated HDACs and administration of butyric acid doses in man for the reduction of alpha-synuclein and Aβ oligomers [78] [129] may inhibit
the zinc sensitive HDACs such as Sirt 1 involved in cell NO homeostasis [129]. LPS sensitive butyric acid
events have been associated with T cell apoptosis and cancer (Figure 5) with butyric acid derivatives important
to cancer treatment [130]. The use of SCFA in nutritional diets has attracted interest to appetite regulation but
the doses of the SCFA have become of concern for use in man and administration of butyric acid may need to be
assessed with relevance to plasma LPS levels that may corrupt the neuroprotective effects of a ketogenic diet
[131].
Sirt 1 activators (nutrients) and inhibitors (drugs, alcohol) have been previously described [11] and their consumption in various countries will determine nuclear receptor function and insulin resistance and determine the
origin of autonomous chronic disease associated with early liver dysfunction linked to organ disease progression.
Diets that are high in NO override the Sirt 1/ p66Shc regulation of cell NO (Figure 5) and mitochondrial apoptosis linked to cell autonomous disease are possibly associated with the acceleration of obesity, diabetes and
neurodegeneration [25] [132]. The major interest in cell anti-aging genes is relevant to specific dietary intake
that allows Sirt 1 cell function to belinked to therapeutic neuropeptide and endocrine responses that lead to the
maintenance of anti-aging cellprocesses with the prevention of NO related apoptosis [133]-[135]. Interactions
between cells in various tissues such as the liver and brain have become important with the brain involved in the
autonomic regulation of liver function. The liver clock [136] may override the automonic regulation of brain
control by autonomous behaviour between cells that may be induced by LPS, mycotoxins or xenobiotics [137]
with dysregulation of neuropeptides and endocrine hormones. Mycotoxins, LPS and xenobiotics that may be
transported to the brain may induce cell desynchrony with appetite dysregulation and overeating related to dysregulation of neuropeptides and endocrine hormones important to insulin and the IGF-1 signaling cascade. The
synergism between LPS, mycotoxin and xenobiotics in diets may override the function of the anti-aging genes
with the liver autonomous to brain regulation with the development of obesity and diabetes. The intestine and its
release of lipid particles such as chylomicrons after a meal [14] has become important to human disease with intestinal release of lipid particles that contain LPS, xenobiotics and mycotoxins. The fat content of diet that releases the number and size of the intestinal particles has become important [138] to the function of the anti-aging genes in liver cells and food restriction (chylomicron release) that allows maintenance of anti-aging gene
function is required. Under fasting conditions or timed meal conditions the release from the intestine of chylomicrons with LPS, xenobiotic or mycotoxin to the liver may allow rapid hepatic metabolism and elimination

Figure 5. The short chain fatty acid butyric acid has been shown to be involved in the inhibition of Sirt 1 activity with effects of butyric acid and LPS on T cell apoptosis and cancer. Butyric acid regulation of brain appetite signals involves other short chain fatty acids such as
acetate and propionic that are important to central appetite regulation. Butyric acid inhibits Sirt
1 with effects on the metabolism of alpha synuclein and amyloid beta metabolism in cells.
Administration of dietary phenyl butyric acid reducesalpha synuclein and amyloid beta oligomers in the brain in mice.
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of various drugs into the bile [122] [137]. Tests for postprandial lipid metabolism in obesity indicate that in the
fed and the fasting conditions dietary chylomicron remnant metabolism is defective with liver programmed cell
death [14]. The various blood tests [22] and tests for postprandial lipid metabolism [14] may not allow early diagnosis of autonomous liver disease independent of appetite regulation that may be the primary disease associated with the current global obesity linked diabetes epidemic relevant to neurodegeneration [3] [22] [139]. The
addition of zinc to the diet may not reverse the cell autonomy and may require the addition of various nutrients
and the removal of various Sirt 1 inhibitors required for anti-aging cell processes. In the developing world, abnormal blood lipids (cholesterol, triglyceride) and liver enzymesmay not interpret the effects of LPS and mycotoxin on anti-aging genes in the liver and brain that are defective and the effects of the anti-aging therapy such
as consumption of a very low carbohydrate or a low fat diet [11] are possibly able to reverse the autonomous
cell behaviour (nuclear-mitochondria interactions) that is linked to the nuclear senescence with mitochondrial
apoptosis [79]. The use of diet as therapy for reversal of the aging process may stabilize the apelinergic system
[25] that is defective in individuals with insulin resistance and important to the optimal function of the brain and
peripheral organs. The anti-aging genes in people at risk for various diseases in global populations may be defective early in life and not connected to DNA methylation profile associated with aging and longevity [140].

5. Discussion
In Western countries and the developing world the metabolic syndrome and NAFLD and neurodegenerative
disease has reached approximate 30% of the global population. Accelerated age related disease associated with
cell senescence interfere the anti-aging genes that are involved with cell growth and healthy aging. Dietary interventions with calorie restriction early in life prevent the tissue accumulation of LPS, mycotoxin, xenobiotics
and drugs by maintenance of post-prandial lipid metabolism associated with delivery of various foreign compounds to the liver relevant to facilitate many tissue cell to cell communications with the prevention of autonomous organ diseases. Anti-aging strategies that involve nutritional diets allow neuropeptides and endocrine
hormones to maintain cell and mitochondrial functions to facilitate nutrient metabolism in the liver and brain.
Prevention of insulin resistance has become the major prevention program in global populations with improvement in zinc intake and maintenance of nitric oxide homeostasis in cells central to prevent early alterations in
multiple anti-aging genes, neuropeptides and endocrine hormones that are associated with appetite regulation,
insulin resistance and cell apoptosis.

6. Conclusion
The regulation of food intake and calorie restriction is important to appetite regulation with relevance to the
progression of chronic disease and neurodegeneration. Appetite dysregulation involves neurons associated with
the suppression of the anti-aging gene Sirt 1 and other anti-aging genes such as Klotho, p66Shc and FOXO1/
FOXO3a that are connected to the programmed cell death (mitochondrial apoptosis) and dysregulation of glucose, lipid and amyloid beta metabolism. Nutritional intervention early in life with the consumption of very low
carbohydrate diets has been recommended that allows maintenance of the autonomic innervation of the liver by
the brain. In the aging process unhealthy diets disconnect the liver from the brain with the ingestion of LPS,
myoctoxin and xenobiotics that induce autonomous liver disease, metabolic disease and neurodegeneration. The
brain and liver dysregulation are connected to various chronic diseases associated with abnormal post-prandial
lipid metabolism, cardiovascular disease, obesity and diabetes. The anti-aging therapy involves low calorie diets
that do not contain LPS, mycotoxin or xenobiotics and these diets maintain brain and liver Sirt 1 activity with
appetite regulation closely linked to zinc and nitric oxide homeostasis connected to the autonomic control of the
liver by the brain.
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